{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-213440","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.356917+00:00","generated_at":"2026-05-14T21:13:11.327967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"confidence":"high","headline":"CG Oncology Q1 net loss widens to $60.2M; BLA submission on track for Q4 2026","bullets":["Net loss of $60.2M ($0.71 per share) vs $34.5M ($0.45) in Q1 2025.","Cash, cash equivalents & marketable securities $1.1B as of March 31, 2026; includes $391.4M from ATM sales.","BLA for cretostimogene in HR BCG-unresponsive NMIBC expected to complete in Q4 2026 after FDA alignment.","Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC anticipated 1H 2026.","Appointed Jim DeTore as CFO in April 2026; he brings 30+ years life sciences experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-213440","json":"https://secwatch.observer/filing/0001193125-26-213440.json","markdown":"https://secwatch.observer/filing/0001193125-26-213440.md","text":"https://secwatch.observer/filing/0001193125-26-213440.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/0001193125-26-213440-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/ck0001991792-20260508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:13:11.327967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}